CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Biomea Fusion, Inc.

BMEA
$100MMicro Cap

Next catalyst

Phase 2March 2027

icovamenib

Type 2 Diabetes

Get an email about BMEA's next catalysts

Track Biomea Fusion (BMEA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline

Catalyst Timeline

2 upcoming, 1 past

Phase 2Next

icovamenib Phase 2 Est. Readout

March 2027~icovamenib64

Estimated primary completion for icovamenib trial (NCT07502495) in Type 2 Diabetes. Topline data typically follows completion by weeks to months.

Source
Phase 2

icovamenib Phase 2 Est. Readout

June 2027~icovamenib60

Estimated primary completion for icovamenib trial (NCT07502508) in Type 2 Diabetes. Topline data typically follows completion by weeks to months.

Source

How BMEA's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaSAN CARLOS
Drug Pipeline

Frequently asked questions

What is in Biomea Fusion, Inc.'s drug pipeline?β†’

CatalystAlert tracks 2 drug candidates in Biomea Fusion, Inc.'s (BMEA) pipeline across Phase 2. Its lead program is icovamenib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Biomea Fusion, Inc.'s next FDA catalyst?β†’

Biomea Fusion, Inc.'s (BMEA) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track BMEA biotech catalysts?β†’

Add BMEA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biomea Fusion, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply